Exploiting Natural Killer Cell Engagers to Control Pediatric B Cell Precursor Acute Lymphoblastic Leukemia

Investigators tested the in vitro effect of different NK cell engagers, which triggered either NKp46 or NKp30 together with CD16A, and target either CD19 or CD20 to induce killing of pediatric B cell precursor acute lymphoblastic leukemia.